KEYNOTE-966: Three-Year Follow-Up for Advanced Biliary Tract Cancer
By Richard S. Finn, MD - Last Updated: March 19, 2025Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Advertisement
The study assessed pembrolizumab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer.
Advertisement
Related Posts
A multivariate analysis revealed HER2-targeted therapy to be an independent prognostic factor for OS.
Dr. Kim discusses how ctDNA compares to traditional imaging and how findings can affect adjuvant treatment decisions for BTC.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
Among 16 patients with confirmed recurrence, ctDNA accurately identified recurrence in 15 patients.
Dr. Pant offered insights on the key findings of zanidatamab's efficacy and safety in HER2-positive BTC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.